<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728363</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037820</org_study_id>
    <nct_id>NCT01728363</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)</brief_title>
  <acronym>Staph</acronym>
  <official_title>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Brian Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple center, open-label, PK study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics in
      hospitalized infants with suspected systemic infection or receiving one of the study drugs
      per local standard of care. Number of participants are 16-32 evaluable per each study drug of
      rifampin, ticarcillin-clavulanate, and clindamycin antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations in plasma will be measured at a central lab using a validated bioanalytical assay. Plasma samples will be drawn according to specific schedules for each drug</measure>
    <time_frame>24 hours</time_frame>
    <description>to determine the Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety review will be performed through monitoring of adverse events each day that the infant is on study</measure>
    <time_frame>7 days after last study dose</time_frame>
    <description>adverse events, serious adverse events, serious suspected adverse reactions, serious adverse reactions, suspected adverse reaction, adverse reactions will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Systemic Infection</condition>
  <arm_group>
    <arm_group_label>Ticarcillin-clavulanate antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort Gestational Age (GA) Postnatal Age (PNA) Dose
&lt;30 weeks &lt;14 days: 75 mg/kg Q12 hrs x 6 doses
&lt;30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses
&lt;30 weeks &gt;45 days-90 days 75 mg/kg Q 6 hours x 6 doses
Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs &amp; both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth &amp; clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin generic antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort GA PNA Dose
&lt;32 weeks &lt;14 days 10 mg/kg Q 24 hours x 4 doses
&lt;32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses
≥32 weeks &lt;14 days 15 mg/kg Q 24 hours x 4 doses
≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses
The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus &amp; staphylococcus epidermis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin Generic Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort GA PNA Dose
&lt;30 weeks &lt;14 days 10 mg/kg Q 12 hours x 6 doses
&lt;30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses
&lt;30 weeks &gt;45 days-120 days 10 mg/kg Q 6 hours x 6 doses
The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.</description>
    <arm_group_label>Clindamycin Generic Antibiotic</arm_group_label>
    <arm_group_label>Rifampin generic antibiotic</arm_group_label>
    <arm_group_label>Ticarcillin-clavulanate antibiotic</arm_group_label>
    <other_name>Ticarcillin-clavulanate generic; Brand Timentin</other_name>
    <other_name>Rifampin generic; Brand Rifadin, Rimatane</other_name>
    <other_name>Clindamycin generic; Brand Cleocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sufficient intravascular access

          -  Suspected systemic infection or receiving 1 of the study drugs per standard of care

          -  informed consent from legal guardian

        Exclusion Criteria:

          -  history of allergic reaction to study drugs

          -  urine output &lt;0.5 mL/hr/kg over the prior 24 hours

          -  serum creatinine &gt;1.7 mg/dl

          -  Any condition in investigator judgment precludes participation because it could affect
             participant safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip B Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute and DUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UFL Health and Baptist</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Children's Hospital</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther. 2014 Oct;96(4):429-37. doi: 10.1038/clpt.2014.134. Epub 2014 Jun 20.</citation>
    <PMID>24949994</PMID>
  </results_reference>
  <results_reference>
    <citation>Ericson JE, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, Clark RH, Benjamin DK Jr, Chu V, Smith PB, Hornik CP; Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee. Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. J Pediatr Gastroenterol Nutr. 2015 Sep;61(3):334-9. doi: 10.1097/MPG.0000000000000792.</citation>
    <PMID>25806675</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonzalez D, Delmore P, Bloom BT, Cotten CM, Poindexter BB, McGowan E, Shattuck K, Bradford KK, Smith PB, Cohen-Wolkowiez M, Morris M, Yin W, Benjamin DK Jr, Laughon MM. Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2888-94. doi: 10.1128/AAC.03086-15. Print 2016 May.</citation>
    <PMID>26926644</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith PB, Cotten CM, Hudak ML, Sullivan JE, Poindexter BB, Cohen-Wolkowiez M, Boakye-Agyeman F, Lewandowski A, Anand R, Benjamin DK Jr, Laughon MM; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Rifampin Pharmacokinetics and Safety in Preterm and Term Infants. Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00284-19. doi: 10.1128/AAC.00284-19. Print 2019 Jun.</citation>
    <PMID>30910891</PMID>
  </results_reference>
  <results_reference>
    <citation>Watt KM, Hornik CP, Balevic SJ, Mundakel G, Cotten CM, Harper B, Benjamin DK Jr, Anand R, Laughon M, Smith PB, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Pharmacokinetics of ticarcillin-clavulanate in premature infants. Br J Clin Pharmacol. 2019 May;85(5):1021-1027. doi: 10.1111/bcp.13882. Epub 2019 Mar 6.</citation>
    <PMID>30710387</PMID>
  </results_reference>
  <results_reference>
    <citation>Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, Hornik CP, Edginton AN. Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects. Clin Pharmacokinet. 2018 May;57(5):577-589. doi: 10.1007/s40262-017-0576-7.</citation>
    <PMID>28779462</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 9, 2012</study_first_submitted>
  <study_first_submitted_qc>November 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2012</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Phillip Brian Smith</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Staphylococcal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Ticarcillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

